Retinoblastoma is the most common primary intraocular malignancy of childhood. Incidence for retinoblastoma approximately 1 in 18.000 live birth worldwide, with mortality 3000 children every year. Mutation in one RB1 allele is constitutional in hereditary bilateral retinoblastoma, whereas somatic mutation in the both allele will rise to the non hereditary unilateral retinoblastoma. The primary goal of treating retinoblastoma is to save the life, followed by preservation of the globe and save the vision. Treatment options consist of chemotherapy, enucleation of the globe, focal treatment with transpupillary thermotherapy, laser photocoagulation, cryotherapy, plaque brachyterapy, external beam radiotherapy,and local chemotherapy
